Significant investment in Primary Care Representatives for
Key Products, Xifaxan® (rifaximin) and
RELISTOR® (methylnaltrexone bromide)
LAVAL, Quebec, Feb. 27, 2017 /PRNewswire/ -- Valeant
Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX)
wholly owned subsidiary, Salix, a leading specialty pharmaceutical
company committed to the prevention and treatment of
gastrointestinal (GI) disorders, today announced that it has
rapidly scaled up its sales force by nearly 40 percent, effective
immediately.
"This is a demonstration of our commitment to GI and its
relative importance to the broader value of our company," said
Joseph C. Papa, Chairman and CEO of
Valeant. "The significant investments in Salix's dedicated
Primary Care Physician (PCP) sales force will help us further reach
patients in need of irritable bowel syndrome with diarrhea (IBS-D)
treatment, and in doing so, will further accelerate growth for our
company."
During the past three months, the company has hired
approximately 250 highly-trained and experienced sales force
representatives and managers to bolster, create and sustain deep
relationships with primary care physicians – key potential
prescribers of Xifaxan® (rifaximin) for IBS-D and
RELISTOR® (methylnaltrexone bromide) tablets for opioid
induced constipation (OIC). With approximately 70 percent of
IBS-D patients initially presenting with symptoms to a primary care
physician, the dedicated PCP sales force will be positioned to
reach even more patients in need of IBS-D treatment.
"This will complement our existing primary care team and will
allow us to capture nearly 75 percent of the primary care market
opportunity," said Mark McKenna,
Senior Vice President and General Manager, Salix
Pharmaceuticals.
In addition, the company has expanded its dedicated pain sales
representatives to strengthen its position in the OIC market, and
established a nurse educator team to educate clinical staff within
top institutions.
About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a
multinational specialty pharmaceutical company that develops,
manufactures and markets a broad range of pharmaceutical products
primarily in the areas of dermatology, gastrointestinal disorders,
eye health, neurology and branded generics. More information about
Valeant can be found at www.valeant.com.
About Salix
Salix Pharmaceuticals is one of the largest gastrointestinal
specialty pharmaceuticals companies in the world. Salix
develops and markets prescription pharmaceuticals products and
medical devices for the prevention and treatment of
gastrointestinal diseases and disorders. For more information on
Salix Pharmaceuticals, visit www.salix.com.
Forward-looking Statements
This press release contains forward-looking statements.
Forward-looking statements may generally be identified by the use
of the words "anticipates," "expects," "intends," "plans,"
"should," "could," "would," "may," "will," "believes," "estimates,"
"potential," "target," or "continue" and variations or similar
expressions. These statements are based upon the current
expectations and beliefs and are subject to certain risks and
uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements. Readers are
cautioned not to place undue reliance on any of these
forward-looking statements. These forward-looking statements
speak only as of the date hereof. Valeant undertakes no obligation
to update any of these forward-looking statements to reflect events
or circumstances after the date of this press release or to reflect
actual outcomes, unless required by law.
Contact Information:
Elif McDonald
514-856-3855
877-281-6642 (toll free)
elif.mcdonald@valeant.com
Media:
Renée Soto
or
Chris Kittredge/Jared Levy
Sard Verbinnen & Co.
212-687-8080
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/valeant-announces-deployment-of-expanded-salix-sales-force-to-capture-untapped-market-opportunity-300413767.html
SOURCE Valeant Pharmaceuticals International, Inc.